Baquiloprim (Standard)
Baquiloprim (Standard) is the analytical standard of Baquiloprim (HY-19581). This product is intended for research and analytical applications. Baquiloprim is an orally active Antibiotic and selective inhibitor of Bacterial Dihydrofolate reductase (DHFR), with an IC50 of 19 nM against E. coli and an IC50 of 190 μM against rat liver dihydrofolate reductase. Baquiloprim is a bacteriostatic broad-spectrum antibacterial agent that acts against Gram-negative and Gram-positive bacteria. Baquiloprim inhibits glucuronidation in cultured hepatocytes. Baquiloprim can be used in research related to Pasteurella haemolytica infection, bacterial infection, Escherichia coli diarrhea, bacterial infection in pigs, and pneumonic pasteurellosis.
For research use only. We do not sell to patients.
- CAS No.: 102280-35-3
- Formula: C17H20N6
- Molecular Weight:308.38
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 102280-35-3
-
Molecular Weight 308.38
-
Formula C17H20N6
-
SMILES
NC1=NC=C(CC2=C3C=CC=NC3=C(N(C)C)C(C)=C2)C(N)=N1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Lewicki J, et al. Oral bioavailability and pharmacokinetics of baquiloprim in dwarf goats. Research in veterinary science. 1995 May;58(3):268-71. [Content Brief]
[2]. White G, et al. Baquiloprim, a new antifolate antibacterial: in vitro activity and pharmacokinetic properties in cattle. Research in veterinary science. 1993 May;54(3):372-8. [Content Brief]
[3]. White DG, et al. Comparison of danofloxacin with baquiloprim/sulphadimidine for the treatment of experimentally induced Escherichia coli diarrhoea in calves. The Veterinary record. 1998 Sep 05;143(10):273-6. [Content Brief]
[4]. Davies AM, et al. Pharmacokinetics of baquiloprim and sulphadimidine in pigs after intramuscular administration. Research in veterinary science. 1994 Jul;57(1):69-74. [Content Brief]
[5]. Sunderland SJ, et al. Efficacy of danofloxacin 18% injectable solution in the treatment of Escherichia coli diarrhoea in young calves in Europe. Research in veterinary science. 2003 Apr;74(2):171-8. [Content Brief]
[6]. Dassanayake L, et al. Administration of a bolus formulation of baquiloprim and sulphadimidine to calves: plasma concentration--time profiles and efficacy in suppressing experimental pneumonic pasteurellosis. Veterinary microbiology. 1994 Jan;38(3):255-62. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Baquiloprim (Standard) Related Classifications
HY-19581R Related Classifications
Powered by Bioz
Keywords
- Baquiloprim (Standard)
- 102280-35-3
- Reference Standards
- Antibiotic
- Bacterial
- Dihydrofolate reductase (DHFR)
- pneumonic pasteurellosis
- Gram-negative bacteria
- E. coli
- Gram-positive bacteria
- rat liver dihydrofolate reductase
- sulphonamides
- bacterial dihydrofolate reductase
- escherichia coli diarrhoea
- hepatocytes
- pasteurella haemolytica infection
- Inhibitor
- inhibitor
- inhibit